-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

BRIEF-Elevation Oncology Announces CEO Transition, Pipeline Prioritization

Reuters · 01/06/2023 08:26
BRIEF-Elevation Oncology Announces CEO Transition, Pipeline Prioritization

- Elevation Oncology Inc ELEV.O:

  • ELEVATION ONCOLOGY ANNOUNCES PIPELINE PRIORITIZATION, REALIGNMENT OF RESOURCES TO ADVANCE EO-3021 AND CEO TRANSITION

  • ELEVATION ONCOLOGY INC - PAUSING FURTHER INVESTMENT IN CLINICAL DEVELOPMENT OF SERIBANTUMAB

  • ELEVATION ONCOLOGY - PRIORITIZING DEVELOPMENT OF EO-3021 & ADDITIONAL PIPELINE PROGRAMS INCLUDING THOSE THROUGH EXISTING PARTNERSHIP WITH CARIS LIFE SCIENCES

  • ELEVATION ONCOLOGY INC - SHAWN LELAND HAS RESIGNED AS CEO

  • ELEVATION ONCOLOGY - REALIGNING RESOURCES TO FOCUS ON ADVANCING EO-3021, ADDITIONAL PIPELINE PROGRAMS EXPECTED TO EXTEND CASH RUNWAY INTO Q4 OF 2024

  • ELEVATION ONCOLOGY INC - INTENDS TO PURSUE FURTHER DEVELOPMENT OF SERIBANTUMAB ONLY IN COLLABORATION WITH A PARTNER

  • ELEVATION ONCOLOGY INC - ANNOUNCES APPROXIMATELY 30% REDUCTION IN WORKFORCE

  • ELEVATION ONCOLOGY INC - JOSEPH FERRA, CFO, APPOINTED AS INTERIM CEO

  • ELEVATION ONCOLOGY INC - AS OF DEC 31, 2022, CO HAD PRELIMINARY UNAUDITED CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALING $90.3 MILLION

Source text for Eikon: ID:

Further company coverage: ELEV.O


((Reuters.Briefs@thomsonreuters.com;))